The vast majority of women diagnosed with ovarian cancer present with advanced-stage disease with a five-year survival rate less than 50%. Studies have shown that in the past, gynecologic oncologists were not routinely collaborating with palliative care physicians resulting in goals of care planning often not occurring until the last 30 days before death. In recent years, professional societies have been increasingly more vocal about the importance of incorporating palliative care early in a patient's disease course. As these calls increase, palliative care clinicians will be likely to comanage patients with ovarian cancer and may benefit from additional targeted education on this unique population. We brought together a team of gynecologic oncology and palliative care experts to collate practical pearls for the care of women with epithelial ovarian cancer. In this article, we use a “Top 10” format to highlight issues that may help palliative care physicians understand a patient's prognosis, address common misconceptions about ovarian cancer, and improve the quality of shared decision making and goals-of-care discussions.
Get full access to this article
View all access options for this article.
References
1.
SiegelRL, MillerKD, JemalA: Cancer statistics, 2017. CA Cancer J Clin, 2017; 67:7–30.
TaylorJS, RajanSS, ZhangN, et al.: End-of-life racial and ethnic disparities among patients with ovarian cancer. J Clin Oncol, 2017; 35:1829–1835.
4.
WrightAA, HatfieldLA, EarleCC, KeatingNL: End-of-life care for older patients with ovarian cancer is intensive despite high rates of hospice use. J Clin Oncol, 2014; 32:3534–3539.
5.
BrownAJ, SunCC, PrescottLS, et al.: Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol, 2014; 135:244–248.
6.
GockleyA, MelamedA, BregarAJ, et al.: Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol, 2017; 129:439–447.
7.
FlemingG, SeidmanJ, LengyelE: Principles and Practice of Gynecologic Oncology, 6th ed. BarakatR, BerhuckA, MarkmanM, RandallM (eds). Philadelphia, PA: Lippincott Williams & Wilkins, 2013.
ArmstrongDK, BundyB, WenzelL, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 2006; 354:34–43.
10.
WenzelLB, HuangHQ, ArmstrongDK, et al.: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol, 2007; 25:437–443.
11.
Otis-GreenS, WakabayashiMT, MorganR, et al.: Palliative care opportunities for women with advanced ovarian cancer associated with intraperitoneal chemotherapy. J Palliat Med, 2013; 16:44–53.
ElattarA, BryantA, Winter-RoachBA, et al.: Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev, 2011:CD007565.
17.
BristowRE, TomacruzRS, ArmstrongDK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol, 2002; 20:1248–1259.
18.
ChiDS, EisenhauerEL, LangJ, et al.: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol, 2006; 103:559–564.
19.
WinterWE3rd, MaxwellGL, TianC, et al.: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol, 2007; 25:3621–3627.
20.
WrightJD, HerzogTJ, NeugutAI, et al.: Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol, 2012; 120:871–881.
21.
VernooijF, HeintzP, WitteveenE, van der GraafY: The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: A systematic review. Gynecol Oncol, 2007; 105:801–812.
22.
du BoisA, RochonJ, PfistererJ, HoskinsWJ: Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review. Gynecol Oncol, 2009; 112:422–436.
23.
WooYL, KyrgiouM, BryantA, et al.: Centralisation of services for gynaecological cancer. Cochrane Database Syst Rev, 2012:CD007945.
24.
VergoteI, TropeCG, AmantF, et al.Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med, 2010; 363:943–953.
25.
KehoeS, HookJ, NankivellM, et al.: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet, 2015; 386:249–257.
26.
WrightAA, BohlkeK, ArmstrongDK, et al.: Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2016; 34:3460–3473.
27.
ChienJ, KuangR, LandenC, ShridharV: Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment. Front Oncol, 2013; 3:251.
28.
RocconiRP, CaseAS, StraughnJM, et al.: Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer. Cancer, 2006; 107:536–543.
29.
SalaniR, KhannaN, FrimerM, et al.: An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol, 2017; 146:3–10.
30.
BristowRE, PuriI, ChiDS: Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol, 2009; 112:265–274.
TranE, SpicelandC, SandhuNP, JatoiA: Malignant bowel obstruction in patients with recurrent ovarian cancer. Am J Hosp Palliat Care, 2016; 33:272–275.
33.
KolomainenDF, DaponteA, BartonDP, et al.: Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol, 2012; 125:31–36.
34.
Paul OlsonTJ, PinkertonC, BraselKJ, SchwarzeML: Palliative surgery for malignant bowel obstruction from carcinomatosis: A systematic review. JAMA Surg, 2014; 149:383–392.
